Gibson, Dunn & Crutcher advised 89bio, Inc. on the offering, and Cooley advised the underwriters. 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, announced the...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is advising ARCA biopharma, Inc. on the transaction, while Gibson, Dunn & Crutcher is advising Oruka Therapeutics and Cooley is advising...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher represented Apogee Therapeutics, Inc. in the offering, and Cooley represented the underwriters. Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company, announced the...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP represented Dianthus Therapeutics, Inc. on the placement. Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation...
You must be a Standard 1 Year member to access this content.
